Supplementary Materials

Supplementary Material for:

Mavoglurant in fragile X syndrome: Results of two randomized, doubleblind, placebo-controlled trials

Elizabeth Berry-Kravis, Vincent Des Portes, Randi Hagerman, Sébastien Jacquemont, Perrine Charles, Jeannie Visootsak, Marc Brinkman, Karin Rerat, Barbara Koumaras, Liansheng Zhu, Gottfried Maria Barth, Thomas Jaecklin, George Apostol, Florian von Raison*

*Corresponding author. E-mail: florian.von_raison{at}novartis.com

Published 13 January 2016, Sci. Transl. Med. 8, 321ra5 (2016)
DOI: 10.1126/scitranslmed.aab4109

This PDF file includes:

  • Fig. S1. ABC-CFX LS mean change from baseline in all patients (CM and PM) after placebo run-in.
  • Fig. S2. ABC-CFX mean change from baseline including placebo run-in.
  • Fig. S3. Change in ABC-CFX versus methylation levels at screening (all patients).
  • Table S1. Change from baseline to week 12 for ABC-CFX subscale scores.
  • Table S2. RBS-R total score at baseline and week 12 and change from baseline to week 12 in all patients (CM and PM).
  • Table S3. SRS total score at baseline and week 12, and change from baseline to week 12 in all patients (CM and PM).
  • Table S4. Number and percentage of patients scoring better on each module of the CNS VS than results achieved by chance (probability) alone in all patients (CM and PM) adult study.
  • Table S5. TEA-Ch change from baseline in raw scores for the three subsets in all patients (CM and PM) adolescent study.
  • Table S6. AEs (≥5% in any group) from baseline to week 12 by treatment (safety population).
  • Table S7. Mavoglurant principal investigators (ordered alphabetically by country).

[Download PDF]